ReviewCureus2025
Risk Factors Associated With Post-stroke Epilepsy: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory-neurological deficit versus metabolic dysregulation: unsupervised clustering and SHAP analysis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke epilepsy (PSE) is a condition that impacts a notable portion of stroke survivors and is linked to worse health outcomes, such as increased risk of death and longer disability. PSE refers to seizures that occur unexpectedly after the first week following a stroke and result from several biological processes, including inflammation and damage from overactive nerve signaling. Existing prediction tools help identify high-risk patients but can be limited by inconsistent evaluation of risk factors. Twenty-seven studies were selected from databases including PubMed, Cochrane Library, and EBSCO using Medical Subject Headings (MeSH) terms and keywords related to stroke, epilepsy, and risk factors. Studies published between 2020 and 2025 were included based on predefined eligibility criteria. During the analysis, a wide range of risk factors were identified, including patient demographics (age, sex, comorbidities, genetic predisposition), stroke features (cortical involvement, lesion size, acute symptomatic seizures), diagnostic findings (early electroencephalogram abnormalities, structural changes on magnetic resonance imaging), and biochemical markers (blood proteins, microRNAs, TNFSF-14). Early interventions, such as hematoma evacuation and thrombectomy, also show potential in reducing PSE risk, while emerging biomarkers, including specific blood proteins and miRNAs, offer promise for early diagnosis. It is recognized that both the occurrence and the timing of early seizure activity may be important for patient outcomes. Interestingly, deep grey matter loss and asymmetrical perivascular spaces were also associated with a higher risk of PSE. Despite these advances, considerable variability remains a challenge across studies. Together, these insights highlight the need for a unified approach to develop better tools for assessing PSE risk, with the ultimate goal of preventing this complication during stroke care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.